Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients

Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients

CD4<sup>+</sup>T-lymphocytes are relevant in the pathogenesis of rheumatoid arthritis (RA), however, their potential involvement in early RA remains elusive. Methotrexate (MTX) is a commonly used disease-modifying antirheumatic drug (DMARD), but its mechanism has not been fully establish...

Full description

Bibliographic Details
Main Authors: Jorge Monserrat Sanz, Cristina Bohórquez, Ana Maria Gómez, Atusa Movasat, Ana Pérez, Lucía Ruíz, David Diaz, Ana Isabel Sánchez, Fernando Albarrán, Ignacio Sanz, Melchor Álvarez-Mon
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
naïve rheumatoid arthritis
CD4+ T-lymphocytes
methotrexate response
IFNγ, IL-17A
STAT expression
Online Access:https://www.mdpi.com/1422-0067/21/18/6847

Internet

https://www.mdpi.com/1422-0067/21/18/6847

Similar Items